KITS Q2 2026 slides: glasses revenue surges 54%, profitability steady

Kits Eyecare reported Q2 2026 revenue of $58.4M (+17.8% YoY) and 15th consecutive quarter of positive adjusted EBITDA ($2.9M; 5.0% margin), with operating cash flow of $7.8M. The key upside driver was glasses revenue, up 54% YoY to $11.1M, lifting glasses to 18.9% of revenue (+440 bps) alongside strong retention (100% sales retention at 24 months vs ~80% industry). Management guided Q3 revenue of $62M–$64M (+14%–18% YoY at midpoint) and adjusted EBITDA margin of 4.0%–6.0%, while shares rose 8.45% to $14.89 and the company ended the quarter with $27.4M cash and zero debt.

Analysis

KITS is transitioning from a niche contact-lens seller into a broader eyewear platform with a materially better customer mix. The key market mechanism is not top-line growth alone; it is that glasses and premium-lens attach raise lifetime value, which should support a higher terminal gross margin and lower implied CAC payback. If management can keep repeat revenue compounding while holding marketing intensity roughly flat, the equity deserves a re-rate versus other small-cap consumer names that are still buying growth at the expense of unit economics.

The second-order winner is the company’s own distribution network: insurance integration and physical retail are not just demand generators, they are data capture points that can improve conversion and reduce churn over time. That said, retail expansion can also become a margin trap if stores behave like expensive billboards rather than profitable local hubs; the market should watch whether new locations create a measurable halo in nearby digital demand within 1-2 quarters. Competitively, this pressure should be felt most by slower-moving optical incumbents that lack a vertically integrated fulfillment stack and cannot match KITS’ speed of merchandising iteration.

The contrarian risk is that investors may be over-penalizing the near-term EBITDA margin dip while underestimating the operating leverage embedded in repeat cohorts. The thesis fails if glasses growth decelerates meaningfully before the new channels scale, or if marketing spend keeps rising faster than customer additions, implying diminishing CAC efficiency. Over the next 3-6 months, the cleanest catalyst is another quarter of premium-lens mix expansion; over 6-18 months, the real test is whether new customer cohorts maintain above-100% retention after the current marketing push normalizes.

Key Decisions for Investors

• Long KITS / KITS.TO on a 1-3 month horizon into the next print; the setup favors a re-rate if revenue growth stays mid-teens and gross margin holds in the high-30s. Risk/reward is attractive if the stock remains below its prior range midpoint, with thesis invalidation on a material slowdown in glasses growth or EBITDA margin below ~4%.
• Use pullbacks to build a tactical long in KITS.TO rather than chasing strength after the gap-up; the near-term upside likely comes from continued guidance credibility, not immediate multiple expansion. Falsify if post-earnings volatility fails to hold gains and the stock retraces to pre-print levels on light volume.
• Avoid overreacting to the marketing-step-up narrative: if next quarter shows customer adds up but repeat revenue stalls, treat that as a warning that CAC is rising faster than cohort quality. Watch marketing % of revenue and repeat revenue mix as the key KPI pair.
• Watch for a 3-6 month call spread structure on KITS only if the stock consolidates and implied vol remains reasonable; the upside catalyst is another beat-and-raise or a visibly successful insurance/channel rollout. If guidance narrows or management sounds cautious on store productivity, do not force the trade.
• Relative-value watch item: long KITS versus a broad consumer-retail proxy only if the market rotates back toward profitable growth. This is a catalyst-driven trade, not a set-and-forget structural short/long; exit if the market stops rewarding growth-at-reasonable-margin profiles.